EUVIMEDEUVIMED entdecken
Open Access

Paraneoplastic Calmodulin Kinase‐Like Vesicle‐Associated Protein ( CAMKV ) Autoimmune Encephalitis

Michael Gilligan, Connie E Lesnick, Yong Guo, Michael J Bradshaw iD, Shafeeq S Ladha, Mihaela Nowak, Maulik P Shah, John R Wittenborn, Eati Basal, Shannon Hinson, Binxia Yang, Divyanshu Dubey iD und 4 weitere

Annals of Neurology · 2024-07 · 96 (1) · 21-33

DOI: 10.1002/ana.26943 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 18.04.2024. Verfasst von Michael Gilligan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Encephalitis, Autoantibodies. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust, NINDS NIH HHS, Wellcome Trust, and Health Research Board (Ireland).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To report an autoimmune paraneoplastic encephalitis characterized by immunoglobulin G (IgG) antibody targeting synaptic protein calmodulin kinase‐like vesicle‐associated (CAMKV).

Methods

Serum and cerebrospinal fluid (CSF) samples harboring unclassified antibodies on murine brain‐based indirect immunofluorescence assay (IFA) were screened by human protein microarray. In 5 patients with identical cerebral IFA staining, CAMKV was identified as top‐ranking candidate antigen. Western blots, confocal microscopy, immune‐absorption, and mass spectrometry were performed to substantiate CAMKV specificity. Recombinant CAMKV‐specific assays (cell‐based [fixed and live] and Western blot) provided additional confirmation.

Results

Of 5 CAMKV‐IgG positive patients, 3 were women (median symptom‐onset age was 59 years; range, 53–74). Encephalitis‐onset was subacute (4) or acute (1) and manifested with: altered mental status (all), seizures (4), hyperkinetic movements (4), psychiatric features (3), memory loss (2), and insomnia (2). Paraclinical testing revealed CSF lymphocytic pleocytosis (all 4 tested), electrographic seizures (3 of 4 tested), and striking MRI abnormalities in all (mesial temporal lobe T2 hyperintensities [all patients], caudate head T2 hyperintensities [3], and cortical diffusion weighted hyperintensities [2]). None had post‐gadolinium enhancement. Cancers were uterine adenocarcinoma (3 patients: poorly differentiated or neuroendocrine‐differentiated in 2, both demonstrated CAMKV immunoreactivity), bladder urothelial carcinoma (1), and non‐Hodgkin lymphoma (1). Two patients developed encephalitis following immune checkpoint inhibitor cancer therapy (atezolizumab [1], pembrolizumab [1]). All treated patients (4) demonstrated an initial response to immunotherapy (corticosteroids [4], IVIG [2]), though 3 died from cancer.

Interpretation

CAMKV‐IgG is a biomarker of immunotherapy‐responsive paraneoplastic encephalitis with temporal and extratemporal features and uterine cancer as a prominent oncologic association. ANN NEUROL 2024;96:21–33

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EncephalitisAutoantibodiesHumansFemaleMiddle AgedAgedMaleHashimoto DiseaseImmunoglobulin GParaneoplastic Syndromes, Nervous SystemMiceAnimals

Substanzen

AutoantibodiesImmunoglobulin G

Autor:innen und Institutionen

  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Department of Neurology, University College Dublin, St Vincent's Hospital Elm Park, Dublin, Ireland.
  • Department of Neurology, Mayo Clinic, Rochester, MN, USA.
  • Department of Neurology, University of Washington and Billings Clinic, Billings, MT, USA.
  • Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.
  • Department of Neurology, Jefferson Hospital, Jefferson Hills, PA, USA.

ORCID-Profile: Michael J Bradshaw, Divyanshu Dubey, Sean J Pittock, Anastasia Zekeridou, Andrew McKeon

Förderung

  • Wellcome Trust
  • NINDS NIH HHS
  • Wellcome Trust, and Health Research Board (Ireland)
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Gilligan, M., Lesnick, C. E., Guo, Y., Bradshaw, M. J., Ladha, S. S., Nowak, M., Shah, M. P., Wittenborn, J. R., Basal, E., Hinson, S., Yang, B., Dubey, D., Mills, J. R., Pittock, S. J., Zekeridou, A., & McKeon, A. (2024). Paraneoplastic Calmodulin Kinase‐Like Vesicle‐Associated Protein ( CAMKV ) Autoimmune Encephalitis. Annals of Neurology, 96(1), 21-33. https://doi.org/10.1002/ana.26943

Vancouver

Gilligan M, Lesnick CE, Guo Y, Bradshaw MJ, Ladha SS, Nowak M, et al. Paraneoplastic Calmodulin Kinase‐Like Vesicle‐Associated Protein ( CAMKV ) Autoimmune Encephalitis. Annals of Neurology. 2024;96(1):21-33. doi:10.1002/ana.26943

BibTeX
@article{Gilligan2024,
  author = {Gilligan, Michael and Lesnick, Connie E and Guo, Yong and Bradshaw, Michael J and Ladha, Shafeeq S and Nowak, Mihaela and Shah, Maulik P and Wittenborn, John R and Basal, Eati and Hinson, Shannon and Yang, Binxia and Dubey, Divyanshu and Mills, John R and Pittock, Sean J and Zekeridou, Anastasia and McKeon, Andrew},
  title = {Paraneoplastic Calmodulin Kinase‐Like Vesicle‐Associated Protein ( CAMKV ) Autoimmune Encephalitis},
  journal = {Annals of Neurology},
  year = {2024},
  volume = {96},
  number = {1},
  pages = {21--33},
  doi = {10.1002/ana.26943}
}
Kostenlos starten →